Showing 1841-1850 of 3314 results for "".
- FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu Lens System in Patients with Cataractshttps://modernod.com/news/fda-grants-atia-vision-approval-to-begin-us-clinical-trial-of-omnivu-lens-system-in-patients-with-cataracts/2482811/Atia Vision has received Investigational Device Exemption (IDE) approval from the FDA to begin a traditional feasibility clinical study of its OmniVu Lens System. This novel IOL is designed to restore dynamic range of vision following catar
- BVI Medical Receives FDA 510(k) Clearance for the Leos Laser Endoscopy Ophthalmic Systemhttps://modernod.com/news/bvi-medical-announces-fda-510k-clearance-of-the-leos-laser-endoscopy-ophthalmic-system/2482743/BVI Medical has received 510(k) clearance from the FDA for its glaucoma surgical system, Leos (Laser Endoscopy Ophthalmic System). Leos introduces a novel, intuitive laser ECP procedure designed to integrate seamlessly into the surgical workflow. According to BVI, it
- Hoya Launches VisuPro Advanced Focus Spectacle Lenses for Patients Experiencing Early Symptoms of Presbyopiahttps://modernod.com/news/hoya-launches-visupro-advanced-focus-spectacle-lenses-for-patients-experiencing-first-symptoms-of-presbyopia/2482724/Hoya has launched its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses, which are designed to help people in their late 30s to mid-40s that are beginning to experience presbyopia. As people enter this age group, they may begi
- Alcon Boosts Femtosecond Laser Portfolio with Acquisition of Lensarhttps://modernod.com/news/alcon-boosts-femtosecond-laser-technology-with-acquisition-of-lensar/2482713/Alcon and Lensar have entered into a definitive merger agreement through which Alcon intends to acquire Lensar for about $356 million. The acquisition includes ALLY Robotic Cataract Laser Treatment System, Lensar’s proprietary Streamline software technology, and Lensar
- Staar Surgical Announces Restructure of Leadershiphttps://modernod.com/news/staar-surgical-announces-restructure-of-leadership/2482705/Staar Surgical announced a series of changes to their leadership structure. These changes come in an effort to better address marketing needs, according to Staar. Warren Foust, Chief Operating Officer, has been promoted to the newly created role of Preside
- Bausch + Lomb Launches Arise Orthokeratology Lens System in the UShttps://modernod.com/news/bausch-lomb-announces-arisetm-orthokeratology-lens-system-in-the-united-states/2482702/Bausch + Lomb announced the US launch of Arise, a lens fitting system designed to use intelligent, cloud-based technology to streamline the orthokeratology lens design process. Orthokeratology is a non-surgical method of vision correction that uses rigid, gas-permea
- Cost, Purchase Factors, and Correct Usage Drive Online Contact Lens Searcheshttps://modernod.com/news/cost-purchase-factors-and-correct-usage-drive-online-contact-lens-searches-according-to-new-research-in-the-us-and-canada/2482671/New research from the Contact Lens Institute (CLI) demonstrates that purchase factors–specificly contact lens retailers and price–are the primary driver of consumer online contact lens-related searches, representing 65% of top 20 searches in the United States and Canada. Oth
- Multifocal Contact Lens in Children Slows Myopia Progression with Lasting Effects, NIH Studyhttps://modernod.com/news/multifocal-contact-lens-in-children-slows-myopia-progression-with-lasting-effects-nih-study/2482643/A new NIH-funded study cites that children who wear multifocal contact lenses to slow progression of myopia maintain their benefits even after they stop wearing contacts as teenagers. This study was a follow-up to the BLINK trial,
- Specialty Contact Lens Division WAVE Eye Care Formedhttps://modernod.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System—three providers of specialty contact lens fitting—have united to form WAVE Eye Care, a division dedicated to providing fully customized specialty contact lenses. According to a j
- CellViva Appoints Three Ophthalmology Leaders to Board of Directorshttps://modernod.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/CellViva, a biopharmaceutical company developing anti-vascular endothelial growth factor—anti-VEGF—therapy for pterygium, announced the appointment of three leaders in ophthalmology to its Board of Directors. According to CellViva, the new directors are: Ad
